Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.48 |
| ▸ | NPY1R | P25929 | 9/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.48 |
| ▸ | NPY2R | P49146 | 5/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | SCTR | P47872 | 1/20 | 0.42 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.41 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808185 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RMC4R | |
| SCHEMBL30512603 | 0.94 | MC4R (0.47) | NPY4RNPY1RNPY5RNPY2RMC4R | |
| SCHEMBL30966840 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29808247 | 0.92 | BACE1 (0.48) | BACE1 | |
| SCHEMBL32682323 | 0.91 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL29376654 | 0.89 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31064805 | 0.89 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2RMC4R | |
| SCHEMBL31005077 | 0.88 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RGLP1R | |
| SCHEMBL9294926 | 0.88 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2RGLP1R | |
| SCHEMBL30873807 | 0.88 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920798-A | Self-assembly material constructed in situ at wound part and preparation method and application thereof | 国家纳米科学中心 | 2022-08-19 | — | — | CN | claimed |
| US-20230295227-A1 | COMPOUNDS FOR USE IN DIAGNOSIS AND/OR MONITORING OF FIBROSIS | ANTAROS TRACER AB (SE) | 2023-09-21 | — | — | US | disclosed |
| EP-4171663-A1 | COMPOUNDS FOR USE IN DIAGNOSIS AND/OR MONITORING OF FIBROSIS | Antaros Tracer AB (SE) | 2023-05-03 | — | — | EP | disclosed |
| CN-115996761-A | Compounds for diagnosing and/or monitoring fibrosis | 安塔罗斯示踪剂公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-114920798-A | Self-assembly material constructed in situ at wound part and preparation method and application thereof | 国家纳米科学中心 | 2022-08-19 | — | — | CN | disclosed |
| CN-114796123-A | Self-assembled peptide nano preparation with anti-hepatic fibrosis function and preparation method and application thereof | 安徽医科大学 | 2022-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295227-A1 | COMPOUNDS FOR USE IN DIAGNOSIS AND/OR MONITORING OF FIBROSIS | COL1A1, INHA, COL2A1 | NPY4R 1439/4885NPY1R 460/4885NPY5R 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.